Mirae Asset Global ETFs Holdings
RYTM icon

Mirae Asset Global ETFs Holdings’s Rhythm Pharmaceuticals RYTM Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23M Sell
29,159
-5,518
-16% -$499K ﹤0.01% 1024
2026
Q1 		$2.98M Sell
34,677
-224
-0.6% -$21.8K ﹤0.01% 1011
2025
Q4 		$3.73M Buy
34,901
+7,779
+29% +$825K 0.01% 903
2025
Q3 		$2.74M Sell
27,122
-5,229
-16% -$485K ﹤0.01% 1006
2025
Q2 		$2.04M Sell
32,351
-2,931
-8% -$179K ﹤0.01% 1087
2025
Q1 		$1.87M Buy
35,282
+2,126
+6% +$118K ﹤0.01% 1177
2024
Q4 		$1.86M Buy
33,156
+654
+2% +$36.1K ﹤0.01% 1179
2024
Q3 		$1.7M Buy
32,502
+2,111
+7% +$101K ﹤0.01% 1231
2024
Q2 		$1.25M Buy
+30,391
New +$1.21M ﹤0.01% 1346

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's RYTM Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Rhythm Pharmaceuticals (RYTM) stake by 16% in Q2 2026, selling an estimated $499K and leaving 29,159 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

Mirae Asset Global ETFs Holdings first reported a position in RYTM in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.73M in Q4 2025. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 29,159 shares of Rhythm Pharmaceuticals worth $3.23M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings sold 5,518 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $499K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1024 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Rhythm Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's Rhythm Pharmaceuticals position peaked at $3.73M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.